The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
Open accessAbstract
BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma. METHODS: A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks; the time to progression of disease and the response rate were primary end points. Crossover from placebo to antibody treatment was allowed, and survival was a secondary end point. RESULTS: Minimal toxic effects were seen, with hypertension and asymptomatic proteinuria predominating. The trial was stopped after the interim analysis met the criteria for early stopping. With 116 patients randomly assigned to treatment groups (40 to placebo, 37 to low-dose antibody, and 39 to high-dose antibody), there was a significant prolongation of the time to progression of disease in the high-dose--antibody group as compared with the placebo group (hazard ratio, 2.55; P<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the low-dose--antibody group and that in the placebo group (hazard ratio, 1.26; P=0.053). The probability of being progression-free for patients given high-dose antibody, low-dose--antibody, and placebo was 64 percent, 39 percent, and 20 percent, respectively, at four months and 30 percent, 14 percent, and 5 percent at eight months. At the last analysis, there were no significant differences in overall survival between groups (P>0.20 for all comparisons). CONCLUSIONS: Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationMolecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
Cited by
Items 101–189 of 189
Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia
Lam, C., Lim, K.-H., & Karumanchi, S. A. (2005) · Hypertension · doi:10.1161/01.hyp.0000187899.34379.b0 · Cited by 406
Renal Vulnerability to Drug Toxicity
Perazella, M. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02050309 · Cited by 403
Rini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 379
Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY
LAM, J. S., SHVARTS, O., LEPPERT, J. T., FIGLIN, R. A., & BELLDEGRUN, A. S. (2005) · Journal of Urology · doi:10.1097/01.ju.0000165693.68449.c3 · Cited by 372
Alternative Vascularization Mechanisms in Cancer
Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70303-5 · Cited by 359
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
Vascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O'Toole, T., Gibbons, J., Belldegrun, A. S., & Figlin, R. A. (2007) · Cancer · doi:10.1002/cncr.22677 · Cited by 350
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 350
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Management of hypertension in angiogenesis inhibitor-treated patients
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 347
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Nowak, D. G., Woolard, J., Amin, E. M., Konopatskaya, O., Saleem, M. A., Churchill, A. J., Ladomery, M. R., Harper, S. J., & Bates, D. O. (2008) · Journal of Cell Science · doi:10.1242/jcs.016410 · Cited by 339
Why is cancer drug discovery so difficult?
Kamb, A., Wee, S., & Lengauer, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2155 · Cited by 339
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Pandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., Beckman, J. A., Harrison, D. G., & Moslehi, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 338
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00868 · Cited by 336
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Self-citationVEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Izzedine, H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., & Soria, J. C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.001 · Cited by 332
Markers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332
Metastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
Mechanisms of Hypertension Associated With BAY 43-9006
Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., & O'Dwyer, P. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0503 · Cited by 324
Mechanisms of Disease: pre-eclampsia
Noris, M., Perico, N., & Remuzzi, G. (2005) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0035 · Cited by 320
Monoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Kaelin, W. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-sup-040025 · Cited by 318
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., Drabkin, H. A., Dutcher, J., Ryba, S., Xia, Q., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5154 · Cited by 315
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Molecular mechanisms of preeclampsia
Mutter, W. P., & Karumanchi, S. A. (2008) · Microvascular Research · doi:10.1016/j.mvr.2007.04.009 · Cited by 314
The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Mechanisms of Angiogenesis · doi:10.1007/3-7643-7311-3_15 · Cited by 312
Preeclampsia: A renal perspective
Karumanchi, S. A., Maynard, S. E., Stillman, I. E., Epstein, F. H., & Sukhatme, V. P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00316.x · Cited by 308
Mourad, J.-J., des Guetz, G., Debbabi, H., & Levy, B. I. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm550 · Cited by 306
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Feldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E., Ishill, N., Patil, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0108 · Cited by 298
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600709 · Cited by 292
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Okwuosa, T. M., Scarabelli, T., Moudgil, R., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1095 · Cited by 290
Perazella, M. A., & Moeckel, G. W. (2010) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2010.09.005 · Cited by 287
Managing Patients Treated with Bevacizumab Combination Therapy
Gordon, M. S., & Cunningham, D. (2005) · Oncology · doi:10.1159/000088481 · Cited by 283
Preeclampsia and eclampsia: the conceptual evolution of a syndrome
Erez, O., Romero, R., Jung, E., Chaemsaithong, P., Bosco, M., Suksai, M., Gallo, D. M., & Gotsch, F. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.12.001 · Cited by 282
Ranpura, V., Hapani, S., Chuang, J., & Wu, S. (2010) · Acta Oncologica · doi:10.3109/02841860903524396 · Cited by 276
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Weber, C. E., & Kuo, P. C. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2011.09.001 · Cited by 271
Anjum, K., Shagufta, B. I., Abbas, S. Q., Patel, S., Khan, I., Shah, S. A. A., Akhter, N., & Hassan, S. S. U. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.125 · Cited by 271
RetractedBiofunctionalized targeted nanoparticles for therapeutic applications
Wang, A. Z., Gu, F., Zhang, L., Chan, J. M., Radovic-Moreno, A., Shaikh, M. R., & Farokhzad, O. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1063 · Cited by 270
Pathophysiology of the Clinical Manifestations of Preeclampsia
Hladunewich, M., Karumanchi, S. A., & Lafayette, R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03761106 · Cited by 270
Pharmacology behind Common Drug Nephrotoxicities
Perazella, M. A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00150118 · Cited by 270
Review: Hydrothermal technology for smart materials
Shandilya, M., Rai, R., & Singh, J. (2016) · Advances in Applied Ceramics: Structural, Functional and Bioceramics · doi:10.1080/17436753.2016.1157131 · Cited by 268
Lubner, S. J., Mahoney, M. R., Kolesar, J. L., LoConte, N. K., Kim, G. P., Pitot, H. C., Philip, P. A., Picus, J., Yong, W.-P., Horvath, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4075 · Cited by 267
Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F., & Wilt, T. J. (2011) · BJU International · doi:10.1111/j.1464-410x.2011.10629.x · Cited by 266
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
Vascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
Hellberg, C., Östman, A., & Heldin, C.-H. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_7 · Cited by 259
Renal-Cell Carcinoma — Molecular Pathways and Therapies
Brugarolas, J. (2007) · New England Journal of Medicine · doi:10.1056/nejme068263 · Cited by 258
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)
JORGE, R., COSTA, R. A., CALUCCI, D., CINTRA, L. P., & SCOTT, I. U. (2006) · Retina · doi:10.1097/01.iae.0000246884.76018.63 · Cited by 258
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
DARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., et al. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1171 · Cited by 253
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Self-citationRole of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Langer, H. F., Chung, K.-J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., DeAngelis, R. A., Roche, P. A., Magotti, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261503 · Cited by 176
The von Hippel-Lindau gene, kidney cancer, and oxygen sensing.
Kaelin, W. G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092803.69761.41 · Cited by 135
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Angiogenesis Inhibitors and Hypertension: An Emerging Issue
Sica, D. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5740 · Cited by 127
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0979 · Cited by 117
A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis
Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J., & Akilesh, S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.011 · Cited by 105
Elimination of Neoangiogenesis for Plaque Stabilization
Kolodgie, F. D., Narula, J., Yuan, C., Burke, A. P., Finn, A. V., & Virmani, R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.083 · Cited by 96
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.030 · Cited by 80
Gyanchandani, R., Ortega Alves, M. V., Myers, J. N., & Kim, S. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0358 · Cited by 73
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Choueiri, T. K., Dreicer, R., Rini, B. I., Elson, P., Garcia, J. A., Thakkar, S. G., Baz, R. C., Mekhail, T. M., Jinks, H. A., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22290 · Cited by 54
Serum Levels of the IL-6 Family of Cytokines Predict Prognosis in Renal Cell Carcinoma (RCC)
Gudbrandsdottir, G., Aarstad, H. H., Bostad, L., Hjelle, K. M., Aarstad, H. J., Bruserud, Ø., Tvedt, T. H. A., & Beisland, C. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02655-z · Cited by 35
Alterations of Microvascular Density in Bone Metastases of Adenocarcinomas
Lórincz, T., Tímár, J., & Szendrói, M. (2004) · Pathology & Oncology Research · doi:10.1007/bf03033743 · Cited by 17
The history of angiogenesis inhibitors
Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15
Relevance of VEGF and nephrin expression in glomerular diseases
Bertuccio, C. A. (2011) · Journal of Signal Transduction · doi:10.1155/2011/718609 · Cited by 12
Metadata
- Authors
- Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-31
- Volume
- 349
- Issue
- 5
- Pages
- 427-434
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046507292
- Cited by
- 2,697
- References
- 19
- FWCI
- 158.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.